Cite

HARVARD Citation

    Nowak, R. et al. (2022). Phase 2 Trial of Rituximab in Acetylcholine Receptor Antibody-Positive Generalized Myasthenia Gravis. Neurology. pp. e376-e389. [Online]. 
  
Back to record